Search results for "Triazoles"

showing 10 items of 132 documents

Disseminated fusariosis in immunocompromised patients

2011

Immunocompromised patients are at high risk of developing serious disseminated infections by opportunistic fungi (Aspergillus, Candida, and Fusarium spp), which frequently present as cutaneous lesions, sometimes as a first sign. Prolonged and deep neutropenia, immunodepressive treatments (systemic steroids and chemotherapy) and severe T-cell immunodeficiency are the most important risk factors. We report 2 patients with acute lymphoblastic leukemia, who developed multiple tender erythematous skin lesions on their legs and arms during chemotherapy treatment. Skin biopsies for histology and culture studies established the diagnosis of Fusarium infection. They received treatment with systemic …

MaleFusariummedicine.medical_specialtyAntifungal Agentsmedicine.medical_treatmentDermatologyNeutropeniaImmunocompromised HostYoung AdultFatal OutcomeAmphotericin BGranulocyte Colony-Stimulating FactormedicineHumansYoung adultImmunodeficiencyVoriconazoleChemotherapyAspergillusbiologybusiness.industryMortality rateMiddle AgedPrecursor Cell Lymphoblastic Leukemia-LymphomaTriazolesmedicine.diseasebiology.organism_classificationDermatologyPyrimidinesFusariosisImmunologyFemaleVoriconazolebusinessmedicine.drugEuropean Journal of Dermatology
researchProduct

Efficacy of posaconazole and amphotericin B in experimental invasive pulmonary aspergillosis in dexamethasone immunosuppressed rats

2007

Objectives: Invasive pulmonary aspergillosis is associated with high mortality. To assess new antifungal therapy options, animal models have to be developed to assess, in an appropriate setting, the activity of new drugs. Methods: Male albino CD rats (125–150 g) were fed with a protein-free diet and received dexamethasone thrice weekly subcutaneously during the whole experiment. After 2 weeks, an inoculum of 10 6 conidia of Aspergillus fumigatus (H11-20) was injected intratracheally. Antifungal treatment was initiated and continued for a total of 7 days. Animals were grouped in numbers of 10. One group of animals served as untreated control, whereas the others were treated with amphotericin…

MaleMicrobiology (medical)medicine.medical_specialtyPosaconazoleAntifungal AgentsDosemedicine.drug_classMicrobial Sensitivity TestsBiologyAspergillosisGastroenterologyDexamethasoneAspergillus fumigatusRats Sprague-DawleyImmunocompromised HostDrug Resistance FungalAmphotericin BAmphotericin BInternal medicinemedicineAnimalsPharmacology (medical)DexamethasoneMycosisPharmacologyDose-Response Relationship DrugAspergillus fumigatusAspergillosis Allergic BronchopulmonaryTriazolesbiology.organism_classificationmedicine.diseaseRatsInfectious DiseasesImmunologyCorticosteroidDrug Therapy Combinationmedicine.drugJournal of Antimicrobial Chemotherapy
researchProduct

A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-sm…

2015

Background: This trial was designed to evaluate the activity and safety of ganetespib in combination with docetaxel in advanced non-small cell lung cancer (NSCLC) and to identify patient populations most likely to benefit from the combination. Patients and methods: Patients with one prior systemic therapy for advanced disease were eligible. Docetaxel (75 mg/m<sup>2</sup> on day 1) was administered alone or with ganetespib (150 mg/m<sup>2</sup> on days 1 and 15) every 3 weeks. The primary end points were progression-free survival (PFS) in two subgroups of the adenocarcinoma population: patients with elevated lactate dehydrogenase (eLDH) and mutated KRAS (mKRAS). Resul…

MaleOncologyHSP90 inhibitormedicine.medical_specialtyLung NeoplasmsPopulationGanetespibPhases of clinical researchDocetaxelAdenocarcinomaNeutropeniaDisease-Free SurvivalProto-Oncogene Proteins p21(ras)Carcinoma Non-Small-Cell LungInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansHSP90 Heat-Shock ProteinsLung cancereducationAgedProportional Hazards Modelseducation.field_of_studyL-Lactate Dehydrogenasebusiness.industryHazard ratioHematologyMiddle AgedTriazolesmedicine.diseaseTreatment OutcomeAdvanced NSCLCOncologyDocetaxelGanetespibAdenocarcinomaFemaleTaxoidsbusinessmedicine.drugAnnals of Oncology
researchProduct

A novel cyclo-oxygenase-2 inhibitor modulates catabolic and antiinflammatory mediators in osteoarthritis.

2004

ITB (6-(p-bromophenyl)amino-7-(p-chlorophenyl)indazolo[2',3':1,5]-1,2,4-triazolo[4,3-a]-1,3,5-benzotriazepine) is a novel inhibitor of cyclo-oxygenase-2 (COX-2) with antiinflammatory activity in animal models. In the present study, we investigated the effect of this compound on the production of catabolic or antiinflammatory mediators in osteoarthritis (OA) cartilage. In OA cartilage explants, ITB inhibited the production of prostaglandin E(2) (PGE(2)), tumour necrosis factor-alpha (TNF-alpha) and matrix metalloproteinase-13 (MMP-13) in a concentration-dependent manner, whereas nitrite was partially reduced. On the contrary, ITB increased the production of interleukin (IL)-10 and the expres…

MaleOxygenaseIndazolesmedicine.medical_treatmentAnti-Inflammatory AgentsOsteoarthritisPharmacologyBiochemistryOsteoarthritismedicineHumansCyclooxygenase InhibitorsProstaglandin E2AgedPharmacologyCyclooxygenase 2 InhibitorsChemistryCatabolismCartilageAnti-Inflammatory Agents Non-SteroidalInterleukinMembrane ProteinsAzepinesTriazolesmedicine.diseaseIsoenzymesInterleukin 10Cytokinemedicine.anatomical_structureCartilageBiochemistryCyclooxygenase 2Prostaglandin-Endoperoxide SynthasesFemalemedicine.drugBiochemical pharmacology
researchProduct

Rufinamide in children and adults with Lennox-Gastaut syndrome: first Italian multicenter experience

2010

This is the first multicenter Italian experience with rufinamide as an adjunctive drug in children, adolescents and adults with Lennox-Gastaut syndrome. The patients were enrolled in a prospective, add-on, open-label treatment study from 11 Italian centers for children and adolescent epilepsy care. Forty-three patients (26 males, 17 females), aged between 4 and 34 years (mean 15.9 ± 7.3, median 15.0), were treated with rufinamide for a mean period of 12.3 months (range 3-21 months). Twenty patients were diagnosed as cryptogenic and 23 as symptomatic. Rufinamide was added to the baseline therapy at the starting dose of 10mg/kg body weight, evenly divided in two daily doses and then increased…

MalePediatricsLennox-Gastaut syndromeAtypical absence seizuresRufinamideLennox–Gastaut syndrome; Rufinamide; Orphan drug; Pediatrics; Epilepsy; Drop attacksInfantilePediatricsSpasmsEpilepsyRufinamideDrop attacks; Epilepsy; Lennox-Gastaut syndrome; Orphan drug; Pediatrics; Rufinamide; Adolescent; Adult; Anticonvulsants; Child; Child Preschool; Drug Therapy Combination; Female; Humans; Intellectual Disability; Italy; Lennox Gastaut Syndrome; Male; Spasms Infantile; Treatment Outcome; Triazoles; Valproic Acid; Young Adult; Neurology (clinical); NeurologyChildPediatricValproic AcidDrop attacksGeneral MedicineSettore MED/39 - Neuropsichiatria InfantileTreatment OutcomeItalyNeurologyAnesthesiaChild PreschoolCombinationVomitingAnticonvulsantsDrug Therapy CombinationFemalemedicine.symptomSpasms Infantilemedicine.drugAdultmedicine.medical_specialtyAdolescentClinical NeurologyIrritabilityYoung AdultDrug TherapyIntellectual DisabilitymedicineHumanspediatrics epilepsyPreschoolAdverse effectLennox–Gastaut syndrome; rufinamide; orphan drug; pediatrics epilepsy; drop attacks; refractory epilepsy.EpilepsyOrphan drugbusiness.industryLennox Gastaut SyndromeValproic Acidrefractory epilepsyTriazolesmedicine.diseaseNeurology (clinical)businessLennox–Gastaut syndromeLennox–Gastaut syndrome
researchProduct

Posaconazole against Candida glabrata Isolates with Various Susceptibilities to Fluconazole

2008

ABSTRACT We investigated the in vitro activities of posaconazole (POS), fluconazole (FLC), amphotericin B (AMB), and caspofungin (CAS) against four clinical isolates of Candida glabrata with various susceptibilities to FLC (FLC MICs ranging from 1.0 to >64 μg/ml). POS MICs ranged from ≤0.03 to 0.5 μg/ml; AMB MICs ranged from 0.25 to 2.0 μg/ml, while CAS MICs ranged from 0.03 to 0.25 μg/ml. When FLC MICs increased, so did POS MICs, although we did not observe any isolate with a POS MIC greater than 0.5 μg/ml. Time-kill experiments showed that POS, FLC, and CAS were fungistatic against all isolates, while AMB at eight times the MIC was fungicidal against three out of four isolates of C. gl…

MalePosaconazoleAntifungal AgentsCandida glabrataMicrobial Sensitivity TestsDrug resistanceBiologyKidneyMicrobiologyMicechemistry.chemical_compoundDrug Resistance Fungalhemic and lymphatic diseasesAmphotericin BmedicineAnimalsHumansExperimental TherapeuticsPharmacology (medical)FluconazolePharmacologyCandida glabrataExperimental modelCandidiasisFungi imperfectiTriazolesbiology.organism_classificationTreatment OutcomeInfectious DiseaseschemistryCaspofunginFluconazolemedicine.drugAntimicrobial Agents and Chemotherapy
researchProduct

Carboxyamidotriazole-Orotate Inhibits the Growth of Imatinib-Resistant Chronic Myeloid Leukaemia Cells and Modulates Exosomes-Stimulated Angiogenesis

2012

The Bcr/Abl kinase has been targeted for the treatment of chronic myelogenous leukaemia (CML) by imatinib mesylate. While imatinib has been extremely effective for chronic phase CML, blast crisis CML are often resistant. New therapeutic options are therefore needed for this fatal disease. Although more common in solid tumors, increased microvessel density was also reported in chronic myelogenous leukaemia and was associated with a significant increase of angiogenic factors, suggesting that vascularity in hematologic malignancies is a controlled process and may play a role in the leukaemogenic process thus representing an alternative therapeutic target. Carboxyamidotriazole-orotate (CTO) is …

MaleResearch ValidityPhysiologyAngiogenesisTumor PhysiologyFusion Proteins bcr-ablCancer Treatmentlcsh:MedicinePharmacologyExosomesCardiovascular PhysiologyBiochemistryPiperazinesHematologic Cancers and Related DisordersMicechemistry.chemical_compoundCell Movementhemic and lymphatic diseasesMolecular Cell BiologyBasic Cancer ResearchMedicine and Health SciencesPhosphorylationPost-Translational ModificationExtracellular Signal-Regulated MAP Kinaseslcsh:ScienceChronic Myelogenous LeukemiaMultidisciplinaryABLNeovascularization PathologicGene Expression Regulation LeukemicChemistryHematologyResearch AssessmentOncologyBenzamidesImatinib MesylateMedicineOncology AgentsAntiangiogenesis Therapymedicine.drugResearch ArticleChronic Myeloid LeukemiaAntineoplastic AgentsResearch and Analysis MethodsCell GrowthCell Line TumorLeukemia Myelogenous Chronic BCR-ABL PositiveLeukemiasCell AdhesionHuman Umbilical Vein Endothelial CellsmedicineAnimalsHumansRNA MessengerPhosphotyrosineBiologyCell ProliferationOrotic AcidTumor microenvironmentCarboxyamidotriazoleInterleukin-8lcsh:RBiology and Life SciencesProteinsCancers and NeoplasmsImatinibTriazolesmedicine.diseaseXenograft Model Antitumor AssaysRetractionExosomePyrimidinesImatinib mesylateDrug Resistance NeoplasmCarboxyamidotriazole Orotatelcsh:QAngiogenesisCell Adhesion MoleculesProto-Oncogene Proteins c-aktDevelopmental BiologyChronic myelogenous leukemiaPLoS ONE
researchProduct

Posaconazole Activity against Candida glabrata after Exposure to Caspofungin or Amphotericin B

2008

ABSTRACT We evaluated the effects of sequential therapy with caspofungin (CAS) or amphotericin B (AMB) followed by posaconazole (POS) against Candida glabrata . The susceptibilities to POS of yeast cells pre-exposed to CAS or AMB were identical to those of untreated cells as shown by standard Clinical and Laboratory Standards Institute broth dilution, cell viability, and disk diffusion methods. We then investigated the activity of sequential regimens in an experimental model of disseminated candidiasis. CAS given at 1 mg/kg/day for 2 days followed by POS at either 15 or 30 mg/kg/day significantly reduced the counts compared to the controls, but this treatment was not superior to the use of …

MaleSettore MED/07 - Microbiologia E Microbiologia ClinicaPosaconazoleAntifungal Agentsmedicine.drug_classAntibioticsColony Count MicrobialCandida glabrataMicrobial Sensitivity TestsBiologyPharmacologyKidneyDrug Administration ScheduleMicrobiologyEchinocandinsLipopeptidesMicechemistry.chemical_compoundCaspofunginAmphotericin BAmphotericin BmedicineAnimalsHumansExperimental TherapeuticsPharmacology (medical)Viability assayPharmacologyCandida glabrataPosaconazole Candida glabrataCandidiasisTriazolesbacterial infections and mycosesbiology.organism_classificationDisseminated CandidiasisRegimenTreatment OutcomeInfectious DiseaseschemistryCaspofunginmedicine.drugAntimicrobial Agents and Chemotherapy
researchProduct

Staphylococcal α-toxin provokes coronary vasoconstriction and loss in myocardial contractility in perfused rat hearts: Role of thromboxane generation

2000

Background —Cardiac performance is severely depressed in septic shock. Endotoxin has been implicated as the causative agent in Gram-negative sepsis, but similar abnormalities are encountered in Gram-positive sepsis. We investigated the influence of the major exotoxin of Staphylococcus aureus, staphylococcal α-toxin, in isolated perfused rat hearts. Methods and Results —α-Toxin 0.25 to 1 μg/mL caused a dose-dependent increase in coronary perfusion pressure that more than doubled. In parallel, we noted a decrease in left ventricular developed pressure and the maximum rate of left ventricular pressure rise (dP/dt max ), dropping to a minimum of <60% of control. These changes were accompani…

MaleThromboxaneIndomethacinProstacyclinVentricular Function LeftHemolysin ProteinsThromboxane A2chemistry.chemical_compoundEdemaPhenylacetatesSulfonamidesHeartAzepinesPerfusionAnesthesiaLactatesVentricular pressuremedicine.symptomCardiology and Cardiovascular Medicinemedicine.drugStaphylococcus aureusmedicine.medical_specialtyBacterial ToxinsExotoxinsIn Vitro TechniquesSepsisContractilityThromboxane A2Physiology (medical)Internal medicinemedicineAnimalsMasoprocolPlatelet Activating FactorRats WistarAspirinL-Lactate Dehydrogenasebusiness.industryTriazolesmedicine.diseaseEpoprostenolMyocardial ContractionRatsEndocrinologychemistryVasoconstrictionPotassiumCoronary perfusion pressurebusinessPlatelet Aggregation InhibitorsVasoconstriction
researchProduct

In vivo consequences of cholesterol-24S-hydroxylase (CYP46A1) inhibition by voriconazole on cholesterol homeostasis and function in the rat retina

2014

International audience; Cholesterol 24S-hydroxylase (CYP46A1) converts cholesterol into 24S-hydroxycholesterol in neurons and participates in cholesterol homeostasis in the central nervous system, including the retina. We aimed to evaluate the consequences of CYP46A1 inhibition by voriconazole on cholesterol homeostasis and function in the retina. Rats received daily intraperitoneal injections of voriconazole (60 mg/kg), minocycline (22 mg/kg), voriconazole plus minocycline, or vehicle during five consecutive days. The rats were submitted to electroretinography to monitor retinal functionality. Cholesterol and 24S-hydroxycholesterol were measured in plasma, brain and retina by gas chromatog…

Malegenetic structuresgliaBiochemistrycholesterol homeostasischemistry.chemical_compoundHomeostasisEnzyme Inhibitorsretinal ganglion cellmedicine.diagnostic_testAnatomyUp-RegulationCYP46A1medicine.anatomical_structureCholesterolRetinal ganglion cellCytokineslipids (amino acids peptides and proteins)MicrogliaNeurogliamedicine.medical_specialtyCentral nervous systemBiophysicsNerve Tissue ProteinsBiologyRetinal ganglionRetinaIn vivoInternal medicinemedicineCholesterol 24-HydroxylaseElectroretinographyvoriconazoleAnimalsRats Wistar[SDV.MHEP.OS]Life Sciences [q-bio]/Human health and pathology/Sensory OrgansMolecular BiologyRetinaCholesterolRetinalCell BiologyTriazolesHydroxycholesterolseye diseasesRatsEndocrinologyPyrimidineschemistrySteroid Hydroxylasessense organs[SDV.AEN]Life Sciences [q-bio]/Food and NutritionElectroretinography
researchProduct